HemaCare Scraps Effort to Create Anti-AIDS Plasma

HemaCare Corp. said it is quitting its five-year experimental project to develop a blood specialty plasma to help fight AIDS.

The Sherman Oaks-based company said closing the research program will result in a $2.9-million charge against its fourth-quarter earnings. The AIDS project, called Immupath, was conducted through the company’s specialty plasma unit.

HemaCare supplies various blood products and services to blood centers.